echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > New study investigates the effect of ORi-guided oxygen titration on hyperoxia-mediated lesions during one-lung ventilation

    New study investigates the effect of ORi-guided oxygen titration on hyperoxia-mediated lesions during one-lung ventilation

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Masimo(NASDAQ: MASI) today released the results of a study published in the Turkish Journal of Medical Sciences .


    Masimo Turkish Journal of Medical Sciences 1

    ORi was launched outside the United States in 2014 and is a non-invasive continuous parameter designed to further understand the oxygen status of patients during supplemental oxygen


    ® ® 2

    The researchers pointed out that OLV is a commonly used technique to simplify various lung operations, and 100% fractional oxygen intake (FiO 2 ) is commonly used to supplement oxygen, which exposes patients to the possibility of hyperoxia-induced lung injury, so they seek to determine ORi Is it possible to "use non-invasive probes during OLV to protect patients from the harmful effects of hyperoxemia"


    2

    Grouping

    Number of subjects

    OLV duration when FiO 2> 60%

    FiO 2 average

    1: Oxygen titration without ORi, low airflow anesthesia (1L/min)

    25

    67.


    71.


    2: Oxygen titration without ORi, high airflow anesthesia (4 L/min)

    28

    97.


    74.


    3: Oxygen titration with ORi, low airflow anesthesia (1L/min)

    25

    39.


    62.


    4: Oxygen titration with ORi, high airflow anesthesia (4 L/min)

    25

    22.


    56.


    Grouping

    Number of subjects

    OLV duration when FiO 2> 60%

    FiO 2 average


    25

    67.


    71.



    28

    97.


    74.
    64 ± 16.
    66%


    3: Oxygen titration with ORi, low airflow anesthesia (1L/min)

    25

    39.
    2 ± 74.
    1 minutes

    62.
    8 ± 13.
    08%


    4: Oxygen titration with ORi, high airflow anesthesia (4 L/min)

    25

    22.
    4 ± 49.
    4 minutes

    56.
    4 ± 11.
    5%


    Grouping

    Number of subjects

    OLV duration when FiO 2> 60%

    FiO 2 average

    Grouping

    Grouping

    Grouping

    Number of subjects

    Number of subjects

    Number of subjects

    OLV duration when FiO 2> 60%

    OLV duration when FiO 2> 60%

    OLV duration when FiO 2> 60% 2

    FiO 2 average

    FiO 2 average

    FiO 2 2 average

    1: Oxygen titration without ORi, low airflow anesthesia (1L/min)

    25

    67.
    6 ± 97.
    5 minutes

    71.
    6 ± 12.
    25%

    1: Oxygen titration without ORi, low airflow anesthesia (1L/min)

    1: Oxygen titration without ORi, low airflow anesthesia (1L/min)

    25

    25

    67.
    6 ± 97.
    5 minutes

    67.
    6 ± 97.
    5 minutes

    71.
    6 ± 12.
    25%

    71.
    6 ± 12.
    25%

    2: Oxygen titration without ORi, high airflow anesthesia (4 L/min)

    28

    97.
    32 ± 99.
    7 minutes

    74.
    64 ± 16.
    66%

    2: Oxygen titration without ORi, high airflow anesthesia (4 L/min)

    2: Oxygen titration without ORi, high airflow anesthesia (4 L/min)

    28

    28

    97.
    32 ± 99.
    7 minutes

    97.
    32 ± 99.
    7 minutes

    74.
    64 ± 16.
    66%

    74.
    64 ± 16.
    66%

    3: Oxygen titration with ORi, low airflow anesthesia (1L/min)

    25

    39.
    2 ± 74.
    1 minutes

    62.
    8 ± 13.
    08%

    3: Oxygen titration with ORi, low airflow anesthesia (1L/min)

    3: Oxygen titration with ORi, low airflow anesthesia (1L/min)

    25

    25

    39.
    2 ± 74.
    1 minutes

    39.
    2 ± 74.
    1 minutes

    62.
    8 ± 13.
    08%

    62.
    8 ± 13.
    08%

    4: Oxygen titration with ORi, high airflow anesthesia (4 L/min)

    25

    22.
    4 ± 49.
    4 minutes

    56.
    4 ± 11.
    5%

    4: Oxygen titration with ORi, high airflow anesthesia (4 L/min)

    4: Oxygen titration with ORi, high airflow anesthesia (4 L/min)

    25

    25

    22.
    4 ± 49.
    4 minutes

    22.
    4 ± 49.
    4 minutes

    56.
    4 ± 11.
    5%

    56.
    4 ± 11.
    5%

    During OLV, patients in groups 1 and 2 undergo oxygen titration without ORi, while groups 3 and 4 use ORi from Masimo Radical-7 ® Pulse Carbon Oxygen-Oxygen Saturation Meter ® and rainbow ® sensors
    .
    For all four groups, SpO 2 and arterial partial pressure of oxygen (PaO 2 ) were routinely measured , while FiO 2 was routinely administered 50% after induction, increased to 60% when OLV was applied, and increased to 70%-100% as needed
    .

    ® ® ® 2 2 2

    The researchers found that the results related to ORi monitoring include: a significant reduction in OLV duration when FiO > 60%, a significant decrease in the average FiO 2 during OLV (as shown in the table above), and a lower PaO 2 record value
    .
    They also found that the duration of FiO 2  > 80% during OLV was strongly correlated with longer hospital stays (p <0.
    001)
    .

    2 2 2

    Compared with the ORi-free group (1 and 2), the observation that the ORi group (3 and 4) has a significantly lower average FiO 2 makes the researchers hypothesize that "the risk of hyperoxia for patients monitored by ORi will be reduced.
    "
    .
    The researchers pointed out: "ORi is not a substitute for arterial blood gas analysis; but it is useful for assessing oxygenation
    .
    In the group without ORi monitors, FiO 2 was significantly higher than 80%
    .
    In addition, this study found that the above patients had a longer hospital stay
    .
    "

    2 2

    There was no significant difference between the ORi values ​​of low-flow (group 3) and high-flow (group 4) queues
    .

    The researchers concluded: “ORi adjusted by peripheral oxygen saturation and blood gas analysis showed that hyperoxemia during OLV in patients with low or high flow anesthesia can be prevented
    .
    Our conclusion is that thoracic anesthesia under the guidance of ORi may be possible Shorten hospital stay and improve patient safety
    .
    "

    prevention

    ORi has not yet been approved by the FDA and has not been marketed in the United States
    .

    FDA

    @Masimo  | #Masimo

    @Masimo

    About Masimo

    About Masimo

    Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide range of industry-leading monitoring technologies, including innovative measurement equipment, sensors, patient monitors, automation and intercommunication solutions
    .
    Our mission is to improve patient outcomes, reduce treatment costs, and deliver non-invasive monitoring to new scenarios and applications
    .
    In 1995, the company launched the Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximeter.
    More than 100 independent and objective studies have shown that its performance is superior to other pulse oximeter technologies 2
    .
    Studies have shown, the SET Masimo ® can help clinicians reduce preterm neonates with severe retinopathy 3 , CCHD improve newborn screening 4 , continuous monitoring of Masimo Patient SafetyNet ™ for postoperative ward, can reduce the Rapid Response Team mobilized , ICU transfer and cost 5-8
    .
    Masimo SET ® is estimated to have been applied to more than 200 million patients in leading hospitals and other medical institutions around the world 9 , and is among the top 10 hospitals in the top 10 hospitals in the U.
    S.
    News and World Report 2020-21 The main pulse oximeter used 10
    .
    Masimo continues to optimize SET ® and announced in 2018 that SpO 2 on the RD SET ® sensor in a mobile stateThe accuracy has been significantly improved, making clinicians more confident that the SpO 2 value they rely on accurately reflects the physiological state of the patient
    .
    In 2005, Masimo launched the rainbow ® pulse carbon oxygen-oxygen saturation meter technology, which realized the non-invasive continuous monitoring of blood components that could only be invasively measured in the past, including total hemoglobin (SpHb ® ), oxygen content (SpOC™), carbon Oxyhemoglobin (SpCO ® ), methemoglobin (SpMet ® ), pulse perfusion variability index (PVi ® ), RPVi™ (rainbow ®  PVi), oxygen reserve index (ORi™)
    .
    In 2013, Masimo launched the Root ® patient monitoring and intercommunication platform, which was designed from the ground up to be as flexible and scalable as possible in order to add other Masimo and third-party monitoring technologies
    .
    Key Masimo additions include the next-generation SedLine ® brain function monitor, O3 ® local oxygen saturation meter, and ISA™ carbon dioxide analyzer with NomoLine ® sampling cable
    .
    Masimo's continuous and spot-inspection monitors Pulse Carbon Oxygen-Oxygen Saturation Meter® family includes devices designed for use in various clinical and non-clinical applications, including wireless wearable technologies (such as Radius- and Radius PPG™), Portable devices (e.
    g.
    Rad-67® ), fingertip pulse oximeter (such as MightySat ® Rx), hospital and home dual-use equipment (such as Rad-97 ® )
    .
    Masimo hospital automation and intercommunication solutions are centered on Masimo Hospital Automation™ platform, including Iris ®  Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView ® , UniView:60™, Masimo SafetyNet™
    .
    For more information about Masimo and its products, please visit style="vertical-align: inherit;"> .
    For published clinical studies of Masimo products, please visit style="vertical-align: inherit;"> .
      

    ® 2 ® 3 Screening 4 5-8 ® 9 10 ® ® 2 2 ® ® ® ® ® ®  ® ® ® ® ® ® ® ® ® ®  ® /feature/

    ORi and RPVi have not obtained FDA 510(k) certification and are not marketed in the United States
    .
    The Patient SafetyNet trademark is used under license from the University HealthSystem Consortium
    .
      

    references

    references
    1. Saracoglu A, Yamansavci Şirzai E, Yildizeli B, Yüksel M, Aykaç ZZ.
      Oxygen Reserve Index Guided Oxygen Titration in One Lung Ventilation with Low Fresh Gas Glow.
        Turkish Journal of Medical Sciences .
      2021 May.
      DOI: 10.
      3906/sag-2009-149 (Saracoglu A, Yamansavci Şirzai E, Yildizeli B, Yüksel M, Aykaç ZZ
      .
      Oxygen titration guided by oxygen reserve index in one-lung ventilation under low fresh gas glow
      .
      Turkish Medical Journal, May 2021.

      DOI: 10.
      3906 /sag-2009-149.
      )
    2. For information about published pulse oximetry clinical trials and the advantages of Masimo SET ® , please visit the company's website at http:// style="vertical-align: inherit;"> .
      Controlled studies include some independent, objective studies, the latter including abstracts presented at scientific conferences and articles in peer-reviewed journals
      .
    3. Castillo A et al.
      Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO Technology.
        Acta Paediatr.
        2011 Feb;100(2):188-92.
      (Castillo A et al
      .
      Transitions through clinical practice and SpO 2 Techniques to prevent retinopathy of prematurity
      .
      "Journal of Pediatrics" February 2011; 100(2):188-92.
      )
    4. de-Wahl Granelli A et al.
      Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.
        BMJ.
        2009;Jan 8;338.
      (de-Wahl Granelli A, etc.

      Pulse The impact of oxygen saturation screening on the detection of catheter-dependent congenital heart disease: a prospective screening study of 39,821 newborns in Sweden
      .
      British Medical Journal, January 8, 2009; 338.
      )
    5. Taenzer A et al.
      Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study.
        Anesthesiology .
      2010:112(2):282-287.
      (Taenzer A et al
      .
      Pulse oxygen saturation The impact of monitoring on treatment events and bed transfers in the intensive care unit: a study of coincidence before and after
      .
      Anesthesiology 2010; 112(2):282-287.
      )
    6. Dartmouth preference Experience at The - Taenzer A et Al Postoperative Monitoring.
        Anesthesia Patient Safety Foundation Newsletter the Spring-Summer 2012.
      Only (Taenzer A, etc.
      .

      .
      Postoperative care - Dartmouth experience
      .
      "Anesthesia patient safety fund will be communication," the spring of 2012 Summer issue
      .
      )
    7. .
      McGrath S et Al Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation.
        Of The Joint Commission and the Patient the Safety Journal ON at Quality 2016 Jul-; 42 is (.
      7):.
      293-302 (McGrath S etc.

      general care unit.
      Monitoring and monitoring management : strategy, design and implementation
      .
      Journal of the Joint Committee on Quality and Patient Safety 2016 July; 42(7):293-302.
      )
    8. McGrath S et al.
      Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity.
        J Patient Saf.
        2020 14 Mar.
      DOI: 10.
      1097/PTS.
      0000000000000696.
      (McGrath S, etc.

      Sedatives and Sedatives Pain-related respiratory arrest in hospitalized patients: the effect of continuous monitoring on patient mortality and severe disease rate
      .
      "Journal of Patient Safety" March 14, 2020.

      DOI: 10.
      1097/PTS.
      0000000000000696.
      )
    9. Estimated value: Masimo archived data
      .
    10. http://health.
      usnews.
      com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview
      .
  • Saracoglu A, Yamansavci Şirzai E, Yildizeli B, Yüksel M, Aykaç ZZ.
    Oxygen Reserve Index Guided Oxygen Titration in One Lung Ventilation with Low Fresh Gas Glow.
      Turkish Journal of Medical Sciences .
    2021 May.
    DOI: 10.
    3906/sag-2009-149 (Saracoglu A, Yamansavci Şirzai E, Yildizeli B, Yüksel M, Aykaç ZZ
    .
    Oxygen titration guided by oxygen reserve index in one-lung ventilation under low fresh gas glow
    .
    Turkish Medical Journal, May 2021.

    DOI: 10.
    3906 /sag-2009-149.
    )
  • Turkish Journal of Medical Sciences
  • For information about published pulse oximetry clinical trials and the advantages of Masimo SET ® , please visit the company's website at http:// style="vertical-align: inherit;"> .
    Controlled studies include some independent, objective studies, the latter including abstracts presented at scientific conferences and articles in peer-reviewed journals
    .
  • ® http:// style="vertical-align: inherit;">Castillo A et al.
    Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO Technology.
      Acta Paediatr.
      2011 Feb;100(2):188-92.
    (Castillo A et al
    .
    Transitions through clinical practice and SpO 2 Techniques to prevent retinopathy of prematurity
    .
    "Journal of Pediatrics" February 2011; 100(2):188-92.
    )
    Acta Paediatr.
      2
  • de-Wahl Granelli A et al.
    Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.
      BMJ.
      2009;Jan 8;338.
    (de-Wahl Granelli A, etc.

    Pulse The impact of oxygen saturation screening on the detection of catheter-dependent congenital heart disease: a prospective screening study of 39,821 newborns in Sweden
    .
    British Medical Journal, January 8, 2009; 338.
    )
  • BMJ.
     
  • Taenzer A et al.
    Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study.
      Anesthesiology .
    2010:112(2):282-287.
    (Taenzer A et al
    .
    Pulse oxygen saturation The impact of monitoring on treatment events and bed transfers in the intensive care unit: a study of coincidence before and after
    .
    Anesthesiology 2010; 112(2):282-287.
    )
  • Anesthesiology
  • Dartmouth preference Experience at The - Taenzer A et Al Postoperative Monitoring.
      Anesthesia Patient Safety Foundation Newsletter the Spring-Summer 2012.
    Only (Taenzer A, etc.
    .

    .
    Postoperative care - Dartmouth experience
    .
    "Anesthesia patient safety fund will be communication," the spring of 2012 Summer issue
    .
    )
  • Anesthesia Patient Safety Foundation Newsletter Fund
  • .
    McGrath S et Al Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation.
      Of The Joint Commission and the Patient the Safety Journal ON at Quality 2016 Jul-; 42 is (.
    7):.
    293-302 (McGrath S etc.

    general care unit.
    Monitoring and monitoring management : strategy, design and implementation
    .
    Journal of the Joint Committee on Quality and Patient Safety 2016 July; 42(7):293-302.
    )
  • The Joint Commission Journal on Quality and Patient Safety management
  • McGrath S et al.
    Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity.
      J Patient Saf.
      2020 14 Mar.
    DOI: 10.
    1097/PTS.
    0000000000000696.
    (McGrath S, etc.

    Sedatives and Sedatives Pain-related respiratory arrest in hospitalized patients: the effect of continuous monitoring on patient mortality and severe disease rate
    .
    "Journal of Patient Safety" March 14, 2020.

    DOI: 10.
    1097/PTS.
    0000000000000696.
    )
  • J Patient Saf.
     
  • Estimated value: Masimo archived data
    .
  • http://health.
    usnews.
    com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview
    .
  • http://health.
    usnews.
    com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview

    Forward-looking statements

    Forward-looking statements

    This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995
    .
    These forward-looking statements include various statements regarding the potential benefits of ORi™, and so on
    .
    These forward-looking statements are based on current expectations of future events that affect us and are subject to risks and uncertainties.
    All risks and uncertainties are difficult to predict, most of which are beyond our control and may lead to our actual The results are very different and diametrically opposite to the results expressed in our forward-looking statements, due to various risk factors, including but not limited to risks related to the following factors: our assumptions concerning the reproducibility of clinical results; our uniqueness to Masimo Belief that these technologies can contribute to positive clinical outcomes and patient safety; and we believe that Masimo non-invasive medical breakthroughs can provide cost-effective solutions and unique advantages Related risks; risks related to COVID-19 ; and other factors discussed in the "Risk Factors" section of the latest version of our report submitted to the U.
    S.
    Securities and Exchange Commission ("SEC").
    These reports are available on the SEC's website www.
    Free on sec.
    gov
    .
    Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations can be proven correct in the future
    .
    All forward-looking statements contained in this press release fully comply with the foregoing cautionary statement
    .
    I would like to remind you not to improperly rely on these forward-looking statements, which are only applicable to today
    .
    Except as may be required by applicable securities laws, we have no responsibility to update, revise or clarify these statements or the "risk factors" contained in the latest version of our report submitted to the SEC, whether as new information or future events.
    The result is still the result of other things
    .

    COVID-19 style="color: #464646;"> 

    Masimo Root® with ORi™ (Photo: Business Wire)



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.